MedTrace Logo

BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

NCT01296932 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2020-08-20

Study results available
· View outcomes & findings →

Summary

Adult patients with chronic lymphocytic leukaemia who experience a relapse after at least two prior treatment regimens may be enrolled in this trial. The trial will examine whether monotherapy with BI 836826 is safe and tolerable at escalating dose levels.

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG

BI 836826

Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-11
Primary Completion
2017-05-30
Completion
2017-07-10

Countries

  • Belgium
  • France
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01296932 on ClinicalTrials.gov